Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 2/20 | 0.58 |
| ▸ | CDK4 | P11802 | 2/20 | 0.58 |
| ▸ | CCND1 | P24385 | 2/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.58 |
| ▸ | PRKCA | P17252 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417633 | 1.00 | CCNE2 (0.58) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6586540 | 1.00 | CCNE2 (0.58) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7522437 | 0.88 | CCNE2 (0.67) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6584610 | 0.86 | CCNE2 (0.63) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL4419691 | 0.86 | CCNE2 (0.63) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL5049317 | 0.86 | CCNE2 (0.63) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL4430981 | 0.82 | CCNE2 (0.57) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL4430976 | 0.82 | CCNE2 (0.57) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL4430984 | 0.82 | CCNE2 (0.57) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7522211 | 0.79 | CCNE2 (0.65) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476676-B2 | Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3β | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1465610-B1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | HOFFMANN LA ROCHE (CH) | 2008-12-31 | — | — | EP | disclosed |
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| EP-1465610-A1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-13 | — | — | EP | disclosed |
| US-20030176484-A1 | Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta | SYNTEX (U.S.A.) LLC | 2003-09-18 | — | — | US | disclosed |
| WO-2003057202-A1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | WO | disclosed |
| EP-1307447-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | CCNE2 1424/4885CDK4 368/4885CCND1 2020/4885 |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | CCNE2 2037/4885CDK4 507/4885CCND1 2283/4885 |
| US-20030176484-A1 | Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta | GSK3B, GSK3A, PHKA1 | CCNE2 2818/4885CDK4 419/4885CCND1 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.